Monday, November 6, 2017
- 9:00AM-11:00AM
-
Abstract Number: 1710
Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells Enhances the Transition of Endothelial to Mesenchymal Cells (Endo-MT) Induced By TGFβ through Down-Regulating PI3/Akt Signaling Pathway By Targeting PIK3R2
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1616
Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1759
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Vasculitis Poster II: ANCA-Associated Vasculitis- 9:00AM-11:00AM
-
Abstract Number: 1707
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1220
Effect of Anti-Diabetic Medications on Fracture Risk in Type II Diabetes Mellitus
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1108
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Metabolic and Crystal Arthropathies Poster I- 9:00AM-11:00AM
-
Abstract Number: 1445
Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1596
Effect of the Metabolic Syndrome on Organ Damage, Renal Function and Mortality in Patients with Systemic Lupus Erythematosus: A Longitudinal Analysis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1476
Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1128
Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout
Metabolic and Crystal Arthropathies Poster I- 9:00AM-11:00AM
-
Abstract Number: 1392
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures- 9:00AM-11:00AM
-
Abstract Number: 1517
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1684
Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1145
Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals